Latest News | Biocon Launches Diabetes, Obesity Management Drug in UK

New Delhi, Feb 28 (PTI) Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement.

Also Read | Bodoland Lottery Result Today, February 28, 2025: Assam State Lottery Sambad Friday Lucky Draw Results Declared, Check Winners List With Ticket Numbers.

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added.

"The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said.

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for February 28, 2025 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added.

Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss.

Liraglutide is a synthetic analog of GLP-1 peptide and is administered as a once-daily injection.

Shares of Biocon were trading 3.17 per cent down at Rs 302.15 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)